Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint

Genzyme Corp. (Nasdaq: GENZ) today announced that its second phase 3 trial of Mozobil^TM (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similar to those reported two weeks ago in non-Hodgkin’s lymphoma.

The combined strength of these two trials – in which patients with two types of cancer achieved more rapid and effective mobilization of stem cells in preparation for transplant than patients treated with current therapies – will support Mozobil’s regulatory approval, commercialization, and likely adoption as a standard of care in transplantation.

The randomized, double-blind, placebo-controlled trial included 302 patients who were undergoing a hematopoietic stem cell transplant (HSCT) for multiple myeloma at medical centers in the United States, Canada, and Europe. Like the previous trial, it examined the effectiveness of Mozobil in increasing the number of hematopoietic stem cells collected for a transplant, comparing the stem cell yield from patients treated with Mozobil following G-CSF to patients treated with placebo following G-CSF.

Source: http://www.genzyme.com